Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Building for big pharma

With acquisition the most likely exit for today's biotech investors, it pays to keep current with the tastes of pharmaceutical firms when launching a venture.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Indicated therapeutic areas of partnering interest for 27 pharmaceutical companies.
Figure 2: Price distributions by phase of development at acquisition announcement for venture-backed companies from 2005 to mid-2012.

References

  1. Big Pharma Mega-Mergers 1995–2014, http://www.datamonitor.com/kc/pharma/

  2. Nutt, D. & Goodwin, G. Eur. Neuropsychopharmacol. 21, 495–499 (2011).

    Article  CAS  Google Scholar 

  3. Tufts Center for the Study of Drug Development. Impact report: new or modified indications for existing drugs have steadily increased in U.S. 13(2) (Tufts University, March/April 2011).

  4. Silicon Valley Bank. Continued rebound: trends in life science M&A. <http://www.svb.com/uploadedFiles/Blogs/10079/continued_rebound.pdf> (July 2012).

  5. Daghlian, M. Life sciences M&A sees fewer billion dollar deals. The Burrill Report (4 January 2013).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sander van Deventer.

Ethics declarations

Competing interests

M.B., G-J.M. and S.v.D. are employed by Forbion Capital Partners.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giniatullina, A., Boorsma, M., Mulder, GJ. et al. Building for big pharma. Nat Biotechnol 31, 284–287 (2013). https://doi.org/10.1038/nbt.2533

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2533

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing